BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 18082990)

  • 1. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas.
    Hennings J; Hellman P; Ahlström H; Sundin A
    Eur J Radiol; 2009 Feb; 69(2):314-23. PubMed ID: 18082990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI.
    Cantwell CP; Setty BN; Holalkere N; Sahani DV; Fischman AJ; Blake MA
    J Comput Assist Tomogr; 2008; 32(5):738-44. PubMed ID: 18830103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of adrenal incidentaloma in patients with a history of malignancy.
    Frilling A; Tecklenborg K; Weber F; Kühl H; Müller S; Stamatis G; Broelsch C
    Surgery; 2004 Dec; 136(6):1289-96. PubMed ID: 15657589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules.
    Ohno Y; Koyama H; Takenaka D; Nogami M; Maniwa Y; Nishimura Y; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
    Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
    J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of delayed enhanced CT and 18F-FDG PET/CT in the evaluation of adrenal masses in oncology patients.
    Park BK; Kim CK; Kim B; Choi JY
    J Comput Assist Tomogr; 2007; 31(4):550-6. PubMed ID: 17882030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings.
    Hennings J; Lindhe O; Bergström M; Långström B; Sundin A; Hellman P
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1410-4. PubMed ID: 16403816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas.
    Yoh T; Hosono M; Komeya Y; Im SW; Ashikaga R; Shimono T; Tsuchiya N; Okada M; Hanada K; Yagyu Y; Nishimura Y; Murakami T
    Ann Nucl Med; 2008 Jul; 22(6):513-9. PubMed ID: 18670858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computed tomography, positron emission tomography, positron emission tomography/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results.
    Plathow C; Staab A; Schmaehl A; Aschoff P; Zuna I; Pfannenberg C; Peter SH; Eschmann S; Klopp M
    Invest Radiol; 2008 Oct; 43(10):737-44. PubMed ID: 18791416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adrenal incidentalomas: etiologic diagnostics and basic therapeutic management. A mini-review].
    Alberti C
    G Chir; 2009 May; 30(5):243-50. PubMed ID: 19505420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical use of digital retrospective image fusion of CT, MRI, FDG-PET and SPECT -- fields of indications and results].
    Lemke AJ; Niehues SM; Amthauer H; Rohlfing T; Hosten N; Felix R
    Rofo; 2004 Dec; 176(12):1811-8. PubMed ID: 15573293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG.
    Minn H; Salonen A; Friberg J; Roivainen A; Viljanen T; Långsjö J; Salmi J; Välimäki M; Någren K; Nuutila P
    J Nucl Med; 2004 Jun; 45(6):972-9. PubMed ID: 15181132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidental PET/CT findings in the cancer patient: how should they be managed?
    Beatty JS; Williams HT; Aldridge BA; Hughes MP; Vasudeva VS; Gucwa AL; David GS; Lind DS; Kruse EJ; McLoughlin JM
    Surgery; 2009 Aug; 146(2):274-81. PubMed ID: 19628085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
    Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
    J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
    Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fever of unknown origin: the role of 18F-FDG PET/CT.
    Keidar Z; Gurman-Balbir A; Gaitini D; Israel O
    J Nucl Med; 2008 Dec; 49(12):1980-5. PubMed ID: 18997040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.